Sanofi collaborates with Shanghai Pharmaceutical to promote three vaccine products in certain broad markets
According to Sanofi, starting from January 1, 2026, Sanofi will leverage the capabilities of its local partner, Shanghai Pharmaceuticals Holding's wholly-owned subsidiary, Hongyao Technology, to provide academic promotion services for vaccination points of three vaccine products: Pentaxim® (pentavalent vaccine), Vaxigrip® (influenza vaccine), and Fluzone® (influenza vaccine) in certain broad market areas, further enhancing accessibility. Sanofi will continue to be responsible for the import, distribution, and all other regional academic promotion work for the three products nationwide. (Jiemian)
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments